PIMREG and autoimmune disease: Also, Astellas Pharma Inc. developed a phenyldifluoromethyl-substituted prolineamide compound (ASP1617) (Table 1) which is a potent and selective CatS inhibitor for the management of autoimmune diseases such as systemic lupus erythematous [59].